RGLS
- Regulus Therapeutics Inc.
()
Overview
Company Summary
Regulus Therapeutics Inc. is a biopharmaceutical company that specializes in the discovery and development of innovative medicines targeting microRNAs. MicroRNAs are small RNA molecules that play a crucial role in regulating gene expression and are involved in a wide range of biological processes.
Regulus focuses on identifying disease-associated microRNAs and developing therapeutic candidates that target and modulate these molecules to treat various diseases. By directly intervening in these regulatory mechanisms, Regulus aims to develop drugs that can restore normal protein function, halt the progression of diseases, and potentially provide more effective treatment options.
The company's research and development efforts primarily focus on chronic hepatitis C virus infection, or HCV, and other liver diseases, such as non-alcoholic steatohepatitis (NASH). They also explore the potential of their microRNA-targeting therapies for the treatment of genetic disorders, cardiovascular diseases, and cancer.
Regulus utilizes its proprietary drug discovery and development platform, which combines deep understanding of microRNA biology, bioinformatics, and advanced technologies to identify promising drug candidates. They conduct preclinical and clinical studies to assess the safety and efficacy of their therapeutic candidates before seeking regulatory approvals and commercializing their products.
Overall, Regulus Therapeutics Inc. is dedicated to harnessing the therapeutic potential of microRNAs to develop innovative medicines that address unmet medical needs and improve patient outcomes in various disease areas.